S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

$329.83
0.00 (0.00%)
(As of 04/1/2024)
Today's Range
$329.83
$329.83
50-Day Range
$313.97
$329.83
52-Week Range
$158.38
$329.99
Volume
5 shs
Average Volume
832,048 shs
Market Capitalization
$12.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$293.92

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
10.9% Downside
$293.92 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$3.17 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.96) to ($7.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.05 out of 5 stars

Medical Sector

907th out of 912 stocks

Pharmaceutical Preparations Industry

417th out of 420 stocks

KRTX stock logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

KRTX Stock News Headlines

Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
KRTX May 2024 210.000 call
1KRTX : Karuna Therapeutics: Q4 Earnings Insights
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Karuna Therapeutics: Getting Sold Short
KRTX Mar 2024 320.000 call
KRTX Mar 2024 260.000 put
KRTX Mar 2024 330.000 call
KRTX Mar 2024 280.000 put
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/20/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
339
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$293.92
High Stock Price Target
$330.00
Low Stock Price Target
$225.00
Potential Upside/Downside
-10.9%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$-433,680,000.00
Pretax Margin
-66,209.48%

Debt

Sales & Book Value

Annual Sales
$654,000.00
Price / Sales
19,239.07
Book Value
$33.24 per share

Miscellaneous

Free Float
33,157,000
Market Cap
$12.58 billion
Optionable
Optionable
Beta
1.18
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Andrew Craig Miller Ph.D. (Age 42)
    Founder and President of Research & Development
    Comp: $835.4k
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 68)
    Chief Medical Officer
    Comp: $751.75k
  • Mr. William Meury (Age 56)
    President, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Alexis Smith
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Mia Kelley J.D.
    General Counsel
  • Mr. Frank Truslow
    Senior Vice President of Corporate Development
  • Mr. Jonathan Rosin
    Chief Human Resources Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor
  • Dr. Ronald N. Marcus M.D. (Age 66)
    Senior Vice President of Medical

KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price target for 2024?

16 brokers have issued 12 month price objectives for Karuna Therapeutics' shares. Their KRTX share price targets range from $225.00 to $330.00. On average, they expect the company's share price to reach $293.92 in the next year. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2024?

Karuna Therapeutics' stock was trading at $316.51 at the beginning of 2024. Since then, KRTX stock has increased by 4.2% and is now trading at $329.83.
View the best growth stocks for 2024 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The business's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.22) earnings per share.

What ETFs hold Karuna Therapeutics' stock?
What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners